Cardiotoxicity related to intrapericardial infusion of bevacizumab in the treatment of lung cancer-mediated malignant pericardial effusion: a case report
The present case indicates that intrapericardial infusion of bevacizumab could lead to cardiotoxicity in MPE patient. Cardiac examinations should be conducted before and after anti-vascular endothelial growth factor treatment.
Authors
- Shilong Wu (ORCID: https://orcid.org/0000-0002-4486-1211)
- Yanjun Lu (ORCID: https://orcid.org/0000-0003-2471-0245)
- Huafeng Liu (ORCID: https://orcid.org/0000-0002-9737-9437)
- Chenyang Xu (ORCID: https://orcid.org/0000-0002-3127-0017)
Institutions
- Ganzhou People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.3389/fphar.2025.1573297
- Citations
- 1
- Primary Topic
- Pericarditis and Cardiac Tamponade
- Type
- article
- Field-Weighted Citation Impact
- 1.39